Background
==========

Squamous cell carcinoma of head and neck (HNSCC), including the oral cavity, pharynx, and larynx, is the sixth most common cancer in the world \[[@B1]\]. Epidemiological studies have shown that this type of cancer is one of those most strongly related to environmental factors, such as tobacco smoking and alcohol consumption. Many chemical carcinogens present in tobacco and alcohol undergo metabolic activation by phase I enzymes, in particular the cytochrome P450 (CYP). The activated metabolites are subsequently subjected to other detoxification steps by phase II enzymes such as glutathione S-transferases (GSTs) and N-acetyltransferases (NATs). It is hypothesized that part of the susceptibility to head and neck cancer may be determined by the inter-individual differences in the bioactivation of procarcinogens and detoxification of carcinogens. *CYP2E1*, which is a major component of the microsomal system involved in the metabolism of ethanol and acetone among phase I enzymes, has been widely studied as a cause of susceptibility to head and neck cancer \[[@B2],[@B3]\].

The *CYP2E1*gene, located on chromosome 10q26.3, is constitutively expressed in human liver and is responsible for the catalysis of xenobiotic. The protein encoded by this gene specifically activates N-nitrosamines and benzene, contained in cigarette smoke \[[@B4]\], and catalyses molecular oxygen to active oxygen forms (e.g., superoxide anion radical, hydrogen peroxide, etc.), which lead to intensified lipid and protein peroxidation, DNA damage, and ultimately carcinogenesis \[[@B5]\]. Several functional polymorphisms have been reported for the *CYP2E1*gene. Two point mutations in the 5\'-flanking region (PstI, RsaI), which are in complete linkage disequilibrium, was found to be associated with higher-transcription and increased enzyme activity \[[@B6]\]. These mutations generate the *CYP2E1*wild (c1) allele and the less common (c2) allele and have been reported as conferring higher risk for developing oral, pharyngeal \[[@B7]\] and lung cancer \[[@B8]\]. Another important polymorphism detectable with DraI in intron 6 is T7632A (rs6413432), a mutation of T to A, which is reported to enhance transcription of the *CYP2E1*gene \[[@B9]\]. Polymorphisms in *CYP2E1*are therefore believed to be risk factors for HNSCC.

A number of studies have investigated the associations between *CYP2E1*polymorphisms and HNSCC susceptibility. However, these studies have yielded contradictory results, with some studies showing a significant association, while others showing no such association. Such inconsistency could be due to the small effect of the polymorphism on HNSCC risk and the relatively small sample-size in each of the published studies. We therefore performed a meta-analysis of the published studies to clarify this inconsistency and to establish a comprehensive picture of the relationship between *CYP2E1*and HNSCC.

Methods
=======

Identification and eligibility of relevant studies
--------------------------------------------------

The literature included in the current analysis was selected using PubMed with keywords \"head and neck\" or \"oral-neoplasms\" or \"larynx\" or \"pharynx\" and \"cancer\" or \"carcinoma\", \"HNSCC\" or \"SCCHN\", \"cytochrome p450 2E1/IIE1\", \"polymorphism\" or \"variant\" and abbreviations of the gene \"Cyp2e1\". No other limits were used during electronic search. All references cited in these studies and previously published review articles were reviewed to identify additional work not indexed by MEDLINE. The analyzed data is drawn from all English language publications up to August 2009.

Only those studies assessing the association between head and neck cancer and the *CYP2E1*gene polymorphisms were included. Eligible studies had to meet the criteria: (1) They were original papers containing independent data, (2) identification of HNSCC was confirmed histologically or pathologically, (3) they provided sufficient data to calculate the odds ratio (OR) or P-value, (4) they used a case-control design, (5) they described genotyping method, equipment and protocols or made reference to them. The major reasons for exclusion of studies were (1) they were family studies, (2) they contained overlapping data, (3) they were review papers.

Quality assessment and data extraction
--------------------------------------

Each article was read and assessed according to the score scale for randomized controlled association study proposed by Dawei et al \[[@B10]\]. In brief, papers were rated according to several items on the scale in relation to two areas: experiment design to minimize potential bias and data analysis. The quality score categorizes studies as of \'\'high\'\' or \'\'low\'\' quality.

For each study, the following information was extracted independently by two investigators: first author\'s surname, publication date, diagnosis criterion, gender, ethnicity, genotyping method, cigarette smoking status, alcohol consumption, total number of cases and controls and the numbers of cases and controls with the three genotypes. The results were compared and disagreements were discussed and resolved with consensus. Where essential information was not presented in articles, every effort was made to contact the authors.

Statistical analysis
--------------------

For the control group of each study, the distributions of genotypes were tested for Hardy-Weinberg equilibrium (HWE) using the Chi-square test. If controls of studies were found not to be in HWE, sensitivity analyses were performed with and without these studies to test the robustness of the findings. For the RsaI/PstI polymorphism, we first estimated the risks of the c1c2 and c2c2 genotypes on HNSCC, compared with the wild-type c1c1 homozygote. The risk of c1c2+c2c2 versus c1c1 on cancers was then evaluated in dominant model. The same evaluation was carried out for the DraI polymorphism. The strength of the association between the *CYP2E1*polymorphism and head and neck cancer risk was measured by odds ratios (ORs) with 95% confidence intervals (CIs).

Cochran\'s χ^2^based Q-statistic test \[[@B11],[@B12]\] and *I*^2^-test \[[@B13]\] were performed to assess possible heterogeneity in the combined studies. If heterogeneity existed, the random effects model (the DerSimonian and Laird method) \[[@B14]\], which yields wider confidence intervals, was adopted to calculate the overall OR value. Otherwise, the fixed effects model (the Mantel-Haenszel method) was used \[[@B15]\]. In addition, sources of heterogeneity were investigated by stratified meta-analyses based on ethnicity (Asian and Caucasian populations), quality (high and low) of the studies, smoking status (ever/never smokers) and alcohol consumption (users/non-users). Asian populations are mainly composed of Chinese and Japanese without Indian. 95% CIs were constructed using Woolf\'s method \[[@B16]\]. The significance of the overall OR was determined by the Z-test. Funnel plots and Egger\'s linear regression test were used to assess evidence for potential publication bias \[[@B17]\]. In order to assess the stability of the result, sensitivity analyses were performed, each study in turn was removed from the total, and the remaining were reanalyzed. The analysis was conducted using Comprehensive Meta Analysis software (Version 1.0.23, BIOSTAT, Englewood, NJ). The type I error rate was set at 0.05. All P-values were two-tailed.

Results
=======

Characteristics of studies
--------------------------

Figure [1](#F1){ref-type="fig"} shows the study selection process. The combined search yielded 88 references. After discarding overlapping references and those which clearly did not meet the criteria, 24 studies were retained. One study \[[@B18]\] was discarded for insufficient data (although we tried to contact the authors to query the data), two \[[@B19],[@B20]\] were discarded as being studies on leukoplakia. As shown in table [1](#T1){ref-type="table"}, 21 case-control studies finally met our criteria for inclusion \[[@B2],[@B3],[@B7],[@B21]-[@B38]\]. 21 studies were identified for the *CYP2E1*-PstI/RsaI polymorphism, including a total of 4951 cases and 5995 controls, and for the DraI polymorphism 9 studies were identified covering a total of 2510 cases and 2162 controls. The detailed characteristics of these studies are summarized in table [1](#T1){ref-type="table"}.

![**Study selection process**.](1471-2407-10-575-1){#F1}

###### 

Demography of the combined studies

  Author, year                             Polymorphism      Ethnicity           Cases   Controls   Genotype distribution in controls                         
  ---------------------------------------- ----------------- ------------------- ------- ---------- ----------------------------------- ----- --- ----- ----- ----
  Olivieri et al.,2009 \[[@B2]\]           PstI/RsaI         Brazilian           153     145        105                                 16    0   /     /     /
                                                                                                                                                              
  Ruwali et al.,2009 \[[@B3]\]             PstI/RsaI, DraI   Indian              350     350        343                                 7     0   253   94    3
                                                                                                                                                              
  Bouchardy et al.,2000 \[[@B7]\]          PstI/RsaI, DraI   French Caucasians   250     172        164                                 8     0   151   20    1
                                                                                                                                                              
  Lucas et al.,1996 \[[@B21]\]             PstI/RsaI, DraI   French Caucasians   96      460        248                                 11    1   368   86    6
                                                                                                                                                              
  Hildesheim et al.,1997 \[[@B22]\]        PstI/RsaI, DraI   Taiwanese           364     320        198                                 113   9   183   123   14
                                                                                                                                                              
  Hung et al.,1997 \[[@B23]\]              PstI/RsaI         Taiwanese           41      122        76                                  42    4   /     /     /
                                                                                                                                                              
  González et al.,1998 \[[@B24]\]          PstI/RsaI         Spaish              75      200        179                                 21    0   /     /     /
                                                                                                                                                              
  Matthia et al.,1998 \[[@B25]\]           PstI/RsaI, DraI   German Caucasians   398     219        165                                 10    0   102   17    2
                                                                                                                                                              
  Morita et al.,1999 \[[@B26]\]            PstI/RsaI         Japanese            145     164        105                                 52    7   /     /     /
                                                                                                                                                              
  Katoh et al.,1999 \[[@B27]\]             PstI/RsaI         Japanese            92      146        95                                  45    7   /     /     /
                                                                                                                                                              
  Kongruttanachok et al.,2001 \[[@B28]\]   PstI/RsaI         Thai                217     297        189                                 103   5   /     /     /
                                                                                                                                                              
  Liu et al., 2001 \[[@B29]\]              PstI/RsaI         American            174     399        384                                 15    0   /     /     /
                                                                                                                                                              
  Neuhaus et al.,2004 \[[@B30]\]           PstI/RsaI, DraI   German              312     299        282                                 13    2   196   39    1
                                                                                                                                                              
  Li et al.,2005 \[[@B31]\]                PstI/RsaI         White American      724     1226       1137                                86    3   /     /     /
                                                                                                                                                              
  Gajecka et al.,2005 \[[@B32]\]           PstI/RsaI         Poland Caucasians   289     316        305                                 18    0   /     /     /
                                                                                                                                                              
  Sugimura et al.,2006 \[[@B33]\]          PstI/RsaI, DraI   Japanese            122     241        164                                 70    7   126   97    18
                                                                                                                                                              
  Gattáet al.,2006 \[[@B34]\]              PstI/RsaI         Brazilian           103     102        96                                  6     0   /     /     /
                                                                                                                                                              
  Marques et al.,2006 \[[@B35]\]           PstI/RsaI         Brazilian           231     212        187                                 25    0   /     /     /
                                                                                                                                                              
  Soya et al.,2008 \[[@B36]\]              PstI/RsaI, DraI   Indian              408     220        212                                 8     0   145   65    10
                                                                                                                                                              
  Shama et al., 2008 \[[@B37]\]            PstI/RsaI         White American      197     416        364                                 39    0   /     /     /
                                                                                                                                                              
  Boccia et al.,2008 \[[@B38]\]            PstI/RsaI, DraI   Italian             210     245        228                                 15    1   224   19    1

Meta-analysis results
---------------------

*CYP2E1*-PstI/RsaI polymorphism
-------------------------------

Our meta-analysis gave an overall OR of 1.96 (95% CI: 1.33-2.90, P \< 0.001, P~Q~= 0.87) for head and neck cancer risk among c2 homozygotes of *CYP2E1*RsaI/PstI polymorphism compared with the wild type. However, no other genetic model gave statistically significant results.

When stratifying for ethnicity, c2 homozygotes were significantly associated with HNSCC in Asian populations with an OR of 2.08(95% CI: 1.34-3.23, P \< 0.001, P~Q~= 0.52) among homozygotes (c2c2 versus c1c1). On the other hand, no such association was detected in Caucasian populations (p \> 0.05 for all models). When studies were stratified for study quality, an overall OR of 1.81 (95% CI: 1.13-2.89, P = 0.013, P~Q~= 0.92) for c2 homozygotes emerged for the high-quality scored studies. These positive associations were also present among low-quality scored studies. Data on genotypes of the PstI/RsaI polymorphism among cases and controls stratified by smoking were available in five studies and by alcohol consumption in four studies. The results of the stratified meta-analyses according to smoking status and alcohol consumption are shown in Table [2](#T2){ref-type="table"}. The overall ORs appeared similar in each subgroup in all three genetic models.

###### 

Stratified analysis of the CYP2E1 *Rsa*I/*Pst*I polymorphism and HNSCC

  Sub-grouped studies   Genetic model             No.of Studies   No.Cases/No.Controls   Test of association   Test of heterogeneity                   
  --------------------- ------------------------- --------------- ---------------------- --------------------- ----------------------- ------- ------- -------
  Overall               c2 carriers vs. wild      21              4892/5995              1.02(0.90-1.17)       0.68                    31.37   0.05    36.26
                                                                                                                                                       
                        c2 homozygotes vs. wild   17              3920/5008              1.96(1.33-2.90)       \<0.001                 9.84    0.87    0
                                                                                                                                                       
                        Dominant                  21              4892/5995              1.08(0.95-1.22)       0.23                    30.68   0.06    34.81
                                                                                                                                                       
  Asians                c2 carriers vs. wild      6               981/1291               1.03(0.86-1.24)       0.69                    5.95    0.31    16.01
                                                                                                                                                       
                        c2 homozygotes vs. wild   6               981/1291               2.08(1.34-3.23)       \<0.001                 4.17    0.52    0
                                                                                                                                                       
                        Dominant                  6               981/1291               1.12(0.94-1.33)       0.18                    4.76    0.44    0
                                                                                                                                                       
  Caucasians            c2 carriers vs. wild      15              3911/4704              1.07(0.82-1.40)       0.57                    25.40   0.03    44.89
                                                                                                                                                       
                        c2 homozygotes vs. wild   11              2939/3717              1.58(0.68-3.68)       0.28                    5.35    0.86    0
                                                                                                                                                       
                        Dominant                  15              3911/4704              1.03(0.86-1.24)       0.49                    25.49   0.03    45.09
                                                                                                                                                       
  High quality          c2 carriers vs. wild      16              3914/4688              1.08(0.86-1.35)       0.48                    26.49   0.033   43.38
                                                                                                                                                       
                        c2 homozygotes vs. wild   13              3173/3913              1.81(1.13-2.89)       0.013                   5.76    0.92    0
                                                                                                                                                       
                        Dominant                  16              3914/4688              1.11(0.90-1.37)       0.29                    24.09   0.064   37.74
                                                                                                                                                       
  Low quality           c2 carriers vs. wild      5               978/1307               1.07(0.84-1.36)       0.57                    4.71    0.31    15.11
                                                                                                                                                       
                        c2 homozygotes vs. wild   4               747/1095               2.36(1.16-4.79)       0.017                   3.70    0.29    19.04
                                                                                                                                                       
                        Dominant                  5               978/1307               1.12(0.81-1.55)       0.46                    6.38    0.17    37.39
                                                                                                                                                       
  Ever-smokers          c2 carriers vs. wild      5               1173/831               0.62(0.34-1.12)       0.11                    8.67    0.07    53.88
                                                                                                                                                       
                        c2 homozygotes vs. wild   2               385/325                0.47(0.15-1.47)       0.19                    0.10    0.74    0
                                                                                                                                                       
                        Dominant                  5               1173/831               0.61(0.33-1.11)       0.10                    8.93    0.063   55.19
                                                                                                                                                       
  Never-smokers         c2 carriers vs. wild      4               549/677                1.40(0.93-2.11)       0.09                    0.44    0.93    0
                                                                                                                                                       
                        c2 homozygotes vs. wild   3               441/431                3.25(0.48-21.70)      0.22                    3.66    0.16    45.43
                                                                                                                                                       
                        Dominant                  4               549/677                1.45(0.98-2.16)       0.06                    1.19    0.75    0
                                                                                                                                                       
  Alcohol- drinkers     c2 carriers vs. wild      4               565/467                1.12(0.51-2.43)       0.76                    8.39    0.039   64.26
                                                                                                                                                       
                        c2 homozygotes vs. wild   2               198/296                1.48(0.34-6.44)       0.59                    0.83    0.36    0
                                                                                                                                                       
                        Dominant                  4               565/467                1.11(0.53-2.29)       0.77                    7.58    0.055   60.43
                                                                                                                                                       
  Non-drinkers          c2 carriers vs. wild      3               653/883                0.92(0.64-1.33)       0.69                    1.31    0.51    0
                                                                                                                                                       
                        c2 homozygotes vs. wild   2               443/370                2.22(0.93-5.30)       0.07                    0.004   0.94    0
                                                                                                                                                       
                        Dominant                  3               653/883                1.07(0.76-1.52)       0.67                    1.08    0.58    0

*CYP2E1*-DraI polymorphism
--------------------------

We also carried out a comprehensive meta-analysis of *CYP2E1*DraI polymorphisms for each ethnic group and for the different quality grades of studies under various genetic models (Table [3](#T3){ref-type="table"}). The overall OR of head and neck cancer was 1.56(95% CI: 1.06-2.27, P = 0.021, P~Q~= 0.37) for homozygotes compared with wild genotype, but no association was observed between T7632A and head and neck cancer using other genetic models.

###### 

Stratified analysis of the CYP2E1 *Dra*I polymorphism and HNSCC

  Sub-grouped studies   Genetic model   No.of Studies   No.Cases/No.Controls   Test of association   Test of heterogeneity                   
  --------------------- --------------- --------------- ---------------------- --------------------- ----------------------- ------- ------- -------
  Overall               AT vs. TT       9               2407/2126              1.15(0.90-1.47)       0.25                    19.92   0.011   59.84
                                                                                                                                             
                        AA vs. TT       9               2407/2126              1.56(1.06-2.27)       0.021                   8.62    0.37    7.21
                                                                                                                                             
                        Dominant        9               2407/2126              1.18(0.94-1.49)       0.13                    18.81   0.016   57.47
                                                                                                                                             
  Asians                AT vs. TT       2               486/561                0.92(0.70-1.19)       0.53                    0.13    0.71    0
                                                                                                                                             
                        AA vs. TT       2               486/561                1.99(1.22-3.24)       0.006                   0.067   0.79    0
                                                                                                                                             
                        Dominant        2               486/561                1.04(0.81-1.34)       0.72                    0.37    0.53    0
                                                                                                                                             
  Caucasians            AT vs. TT       7               1921/1601              1.24(0.92-1.66)       0.15                    14.61   0.02    58.95
                                                                                                                                             
                        AA vs. TT       7               1921/1601              1.08(0.59-1.97)       0.78                    6.18    0.40    2.98
                                                                                                                                             
                        Dominant        7               1921/1601              1.22(0.90-1.65)       0.18                    16.29   0.01    63.17
                                                                                                                                             
  High quality          AT vs. TT       7               2189/1663              1.12(0.83-1.51)       0.43                    18.33   0.005   67.27
                                                                                                                                             
                        AA vs. TT       7               2189/1663              1.28(0.81-2.03)       0.28                    5.89    0.43    0
                                                                                                                                             
                        Dominant        7               2189/1663              1.13(0.85-1.49)       0.38                    17.11   0.009   64.93
                                                                                                                                             
  Low quality           AT vs. TT       2               218/499                1.19(0.82-1.72)       0.35                    1.59    0.20    37.10
                                                                                                                                             
                        AA vs. TT       2               218/499                2.36(1.20-4.63)       0.012                   0.56    0.45    0
                                                                                                                                             
                        Dominant        2               218/499                1.35(0.95-1.92)       0.085                   1.25    0.26    20.00

After stratification for ethnicity, we observed an OR of 1.99(95% CI: 1.22-3.24, P = 0.006, P ~Q~= 0.79) for the DraI polymorphism in Asian populations among homozygotes (AA versus TT), whereas no such association was observed in Caucasian populations. After stratification for study quality, an overall OR of 2.36 (95% CI: 1.20-4.63, P = 0.012, P~Q~= 0.45) for homozygotes emerged for the low-quality scored studies but no such association was observed among high-quality studies (Table [3](#T3){ref-type="table"}).

Sensitivity analyses and Publication bias
-----------------------------------------

Most studies indicated that the frequency distributions of genotypes in the controls were consistent with Hardy-Weinberg equilibrium (HWE), whereas deviations from HWE were observed in three studies of the PstI/RsaI polymorphism \[[@B21],[@B28],[@B30]\]. However, the corresponding pooled ORs were not substantially altered whether or not these studies were included (Data not shown). In addition, sensitivity analysis indicated that no single study influenced the pooled OR qualitatively, suggesting that the results of this meta-analysis are stable.

Begger\'s funnel plot and Egger\'s test were used to assess publication bias. The shape of the funnel plots was symmetrical (Additional file [1](#S1){ref-type="supplementary-material"}). The Egger test provided evidence that there was no publication bias among the studies included (p \> 0.05, for all).

Discussion
==========

In the present meta-analysis, we examined the association between two widely studied *CYP2E1*polymorphisms (PstI/RsaI, DraI) and head and neck cancer risk. We found that the variant homozygote of the *CYP2E1*PstI/RsaI polymorphism was significantly associated with cancer risk in the overall comparisons, compared with the wild homozygote. We also observed a significant association between the *CYP2E1*DraI polymorphism and cancer risk for homozygote in the overall comparisons.

As for the PstI/RsaI polymorphism of *CYP2E1*, our result showed a significantly high cancer risk for the c2 homozygote in Asian populations, with no such association being found among Caucasian population under any of the three genetic models. Ethnic differences may attribute to these different results, since the distributions of the less common c2 allele were different between various races, with a prevalence of \~25-50% and 5-10% among Asians and Caucasians, respectively \[[@B39]\]. The c2 variant allele frequency did reach a statistically significant level among Asians, while in the Caucasian populations, the lack of significant association might be explained by the substantially lower statistical power caused by the lower prevalence of *CYP2E1*c2 allele (5-10% against 25-50% for Asians).

*CYP2E1*is presumed to confer susceptibility to HNSCC by metabolizing carcinogens but, unfortunately, few of the studies explored the interaction between the *CYP2E1*genotype and smoking habits or alcohol consumption. This may be due to the low statistical power of the individual studies to detect such interactions; but all the studies which collected these data were utilized for this meta-analysis. The stratified meta-analyses of all the data on the PstI/RsaI genotype and smoking habits or alcohol consumption with respect to head and neck cancer risk produced no statistically significant results. These results suggest that when the environmental and genetic risk factors are both present, the combined effect on head and neck cancer seems to be no longer than additive of the separate effects. However, we cannot ignore the fact that owing to the low prevalence of c2 homozygotes in each study, even when data are pooled, the statistical power to detect an interaction remains low.

In addition, the DraI polymorphism was associated with an increased cancer risk among Asians but not among Caucasians, suggesting an ethnic difference in terms of genetic and environmental factors \[[@B40]\]. However, only two studies of the DraI polymorphisms used Asian population data and it is therefore probable that the observed ethnic differences were simply due to chance, given that studies with small sample size may have insufficient statistical power to detect a slight effect. Additional studies are therefore required to further validate ethnic differences in the effect of DraI polymorphisms on cancer risk, especially in Asian populations.

Currently, the mechanism whereby the rare allele of the RsaI/PstI and DraI polymorphisms increases the risk of head and neck cancer risk are still not clear. *CYP2E1*is a phase I enzyme, which plays an essential role in the metabolic activation of low molecular weight compounds and pro-carcinogens such as N-nitrosamines, benzene, and halogenated hydrocarbons. There is strong evidence from in vitro studies suggesting that the rare allele of the RsaI/PstI polymorphisms in the *CYP2E1*gene probably confers a higher risk of HNSCC susceptibility by increasing transcriptional and enzyme activity \[[@B6]\]. Thus, the c2/c2 genotypes may be more liable to metabolically activate mutagens and carcinogens. As for the rare allele of the DraI polymorphism of the *CYP2E1*gene, in vitro expression studies indicate that it is associated with increased transcriptional activity \[[@B9]\]. The AA genotypes may therefore have more ability to metabolize mutagens and pro-carcinogens.

Some limitations should be considered when interpreting our results, in addition to those inherited from the meta-analysis. First, our results are based on unadjusted estimates, whereas adjustments for factors such as age and sex would produce a more precise analysis. The lack of this kind of information may cause serious confounding bias. Further large and well-designed studies need to be performed to further confirm all these results. Secondly, the subgroup meta-analyses dealing with interactions between the *CYP2E1*genotype and smoking habits/alcohol consumption are based on the small number of studies where such information is available. Nevertheless the number of subjects included in this part of the analysis comprised the largest sample of all. Third, the quality score of the individual studies included in our meta-analysis was assessed on the basis of trying to minimize the potential for selection bias, misclassification related to exposure, collection of data on potential confounders and method of statistical analysis. No validated quality assessment system currently exists, and it is evident that our quality scale has a subjective component.

Conclusions
===========

In summary, this may be the first systematic and comprehensive meta-analysis of *CYP2E1*and HNSCC. Our results indicate that the *CYP2E1*-PstI/RsaI and DraI polymorphisms may be a risk factor for head and neck cancer in Asian populations, and particularly for individual homozygotes for the unfavourable gene variant. However additional large studies are needed to validate our findings. Future studies should use standardized unbiased genotyping methods as well as homogeneous cancer patients and well-matched controls.
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